This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Bio-Techne's New Simple Plex Cartridge Boosts Protein Segment
by Zacks Equity Research
Bio-Techne (TECH) introduces a multi-analyte cartridge format for the Ella immunoassay platform. The cartridge provides more accurate results at a lower cost.
ABIOMED (ABMD) Banks on Impella Platform, Forex a Concern
by Zacks Equity Research
ABIOMED (ABMD) is focusing heavily in its proprietary Impella Platform to enhance customer base.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex Corp (LMNX) is focusing on augmenting its portfolio strength through new FDA approvals.
Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day
3 Healthcare Stocks to Buy on Renewed Obamacare Repeal Talks
by Benjamin Rains
Healthcare has been a newsworthy topic for decades, and that is unlikely to cease anytime soon as the Republican effort to repeal and replace the Affordable Care Act, or Obamacare, ramps up ahead of a key Sept. 30 deadline.
Here's Why Investors Should Buy Luminex (LMNX) Right Now
by Zacks Equity Research
The market is upbeat about Luminex's (LMNX) recent partnership with Sutter Health and FDA approvals.
Luminex (LMNX) Down 2.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Luminex (LMNX) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex Partners Sutter Health to Boost Molecular Testing
by Zacks Equity Research
The latest development is a significant addition to Luminex's (LMNX) molecular testing and diagnostic portfolio. The company has a broad product portfolio that comprises the advanced ARIES platform.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex (LMNX) has a broad range of products that are built on advanced technology. Also, it has collaborative agreements with several companies, which should help expand the use of its products.
Luminex (LMNX) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
Luminex's (LMNX) assay business will be its key driver over the long term. The FDA go-ahead for Luminex ARIES Bordetella and ARIES C. Difficile assay were the key highlights of the second quarter.